Enhertu receives EU approval recommendation for HER2+ solid tumors By Investing.com

The EMA committee recommended approval of Enhertu for adult patients with unresectable or metastatic HER2 positive solid tumors after prior treatment, a positive regulatory step that could expand the drug’s EU commercial opportunity. Phase 2 data showed objective response rates of 51.4% in DESTINY-PanTumor02, 52.9% in DESTINY-Lung01, and 46.9% in DESTINY-CRC02, with consistent safety across trials. Separately, Daiichi Sankyo reported Q4 FY2025 EPS of 70.02 JPY versus 55.37 JPY expected and revenue of 589.71 billion JPY, reinforcing a solid fundamental backdrop.

Analysis

AZN’s near-term setup improves less from the headline approval itself than from the shape of the opportunity set it unlocks: pan-tumor label expansion raises the probability that Enhertu becomes a multi-indication oncology franchise rather than a disease-specific product. That matters because ADC economics scale disproportionately with breadth of eligible patients and repeat prescriber familiarity, which should support both duration of revenue and bargaining power in future partnership discussions. The second-order winner is the European launch machinery around oncologists, testing, and infusion capacity; the loser is any competing HER2-directed or later-line salvage therapy that was relying on “no satisfactory options” patients staying diffuse and small.

The key risk is not regulatory approval but the market’s growing sensitivity to pulmonary toxicity. Even when efficacy is strong, ILD/pneumonitis creates a low-frequency, high-salience overhang that can cap label expansion velocity and force more conservative physician uptake, especially in community settings. Expect the biggest commercial inflection in months, not days: EU Commission clearance is likely a formality, but reimbursement, sequencing, and test adoption will determine whether the opportunity converts into visible European sales before the next earnings cycle.

The consensus may be underweighting the earnings quality angle for AZN/Daiichi: a broader Enhertu footprint increases mix contribution from a high-gross-margin asset just as the companies need catalysts that are less dependent on macro/pharma sentiment. The contrarian risk is that the positive opinion is already well-anticipated and the stock reaction may be muted unless management uses the approval to raise medium-term oncology guidance. If that doesn’t happen, the trade becomes a fundamentals story rather than a headline trade, and upside can stagnate even while the science remains intact.

Key Decisions for Investors

• Long AZN on pullbacks over the next 1-3 weeks into EU Commission confirmation; target a 6-10% rerating if management frames Enhertu as a broader 2026 growth bridge, with downside limited to a 2-3% giveback if the market had already priced approval.
• Pair trade: long AZN / short a basket of HER2-adjacent oncology laggards with weaker late-line pipelines over 1-2 months; the setup favors companies whose valuation depends on protecting niche indications from ADC share capture.
• If options liquidity is available, buy 3-6 month AZN calls financed by selling upside farther out-of-the-money; this expresses the view that commercial uptake, not approval, is the main catalyst, while preserving convexity if oncology guidance improves.
• Avoid chasing immediately after the EU Commission decision; wait for either reimbursement commentary or management guidance, since the trade’s edge is in the second leg of adoption rather than the first headline.
• For event-driven accounts, consider a small long/short relative value position favoring AZN over broader European pharma peers for 2-4 quarters, as Enhertu’s category expansion should support above-peer growth and margin mix.